ArticleMedical oncology (Northwood, London, England)2024

Structure-based multitargeted docking screening, pharmacokinetics, DFT, and dynamics simulation studies reveal mitoglitazone as a potent inhibitor of cellular survival and stress response proteins of lung cancer.

Abdulkarim S Binshaya et al.PubMed ↗Publisher ↗

No numbers read from the abstract.